Filling the need for trusted information on national health issues…

Trending on kff Ebola Marketplaces Consumer Resources

Kaiser Daily Global Health Policy ReportClinical Research/R&D Search Results « » The Henry J. Kaiser Family Foundation

Clinical Research/R&D

  • your selections
Clear Search

Filter Results

date

Tags

  • results
The Henry J. Kaiser Family Foundation

White House Plans To Request More Funding To Develop Antibiotics, ‘Address Global Threat Of Infectious Disease’

CQ HealthBeat: Obama to Seek Funding Boost for Antibiotic Development “The health care portion of President Barack Obama’s State of the Union address was mostly focused on a call for more research dollars for ‘precision medicine.’ But the new plan will also fund efforts to fight antibiotic resistance — an…

News Summary Read More
The Henry J. Kaiser Family Foundation

Whole Plant Artemisia Better Malaria Treatment In Mice Than Refined Active Ingredient, Study Shows

New York Times: Hold the Drug, Go Straight to the Source “Ground-up artemisia plants, from which the anti-malaria drug artemisinin is derived, appear to work much better than the refined drug does by itself, according to research at the University of Massachusetts…” (McNeil, 1/26).

News Summary Read More
The Henry J. Kaiser Family Foundation

Fast-Track Efforts To Produce Experimental Ebola Treatments Taking Longer Than Expected

New York Times: Fast Track on Drug for Ebola Has Faltered “…Six months [after it was first used in two American aid workers with Ebola], very little [of the experimental drug ZMapp] has been produced, diminishing the chances that the drug can be used to treat large numbers of patients…

News Summary Read More
The Henry J. Kaiser Family Foundation

GSK Ships Experimental Ebola Vaccine To Liberia; Trial Of 2 Vaccine Candidates To Begin There Soon

BBC News: Ebola crisis: Experimental vaccine ‘shipped to Liberia’ “The first batch of an experimental vaccine against Ebola is on its way to Liberia. The shipment will be the first potentially preventative medicine to reach one of the hardest hit countries…” (Mundasad, 1/23). CQ HealthBeat: Top Ebola Vaccine Candidates to…

News Summary Read More
The Henry J. Kaiser Family Foundation

Experts At European Parliament Session Outline Challenges In TB Drug Development

EurActiv: Developing countries urged to produce TB vaccines locally “Even though one third of the global population have the microbes that cause tuberculosis (TB), pharmaceutical companies still have little incentive to produce the drugs that can combat the deadly but curable disease. Speaking at the European Parliament on Wednesday (21…

News Summary Read More
The Henry J. Kaiser Family Foundation

Global Health Research Ranking Table Puts Oxford Atop U.K. List

Science Magazine: University of Oxford named United Kingdom’s global health front-runner “Only a handful of U.K. universities are deeply involved in the fight to improve global health, according to a new ranking table released yesterday at the United Kingdom’s Houses of Parliament. The idea behind the list — which follows…

News Summary Read More
The Henry J. Kaiser Family Foundation

Bureaucratic Delays Keep India’s Vulnerable From Receiving Life-Saving TB Treatment

Wall Street Journal: Inside India: The Deadly Effects of Red Tape Getta Anand, senior writer for the Wall Street Journal based in Mumbai “Red tape and over-regulation can kill. As Prime Minister Narendra Modi fights to loosen bureaucrats’ stifling grip on the economy, he also needs to ease Indians’ access…

News Summary Read More
The Henry J. Kaiser Family Foundation

Congress Should Fix FDA Neglected Disease Drug Voucher Program’s Flaws

PLOS “Speaking of Medicine”: FDA Voucher for Leishmaniasis Treatment: Can Both Patients and Companies Win? Bernard Pécoul, executive director of the Drugs for Neglected Diseases initiative (DNDi), and Manica Balasegaram, executive director of the MSF Access Campaign, discuss how flaws in the FDA Priority Review Voucher (PRV) program have rewarded…

News Summary Read More
The Henry J. Kaiser Family Foundation

J&J Receives $117M Grant From E.U.-Supported Innovative Medicines Initiative For Ebola Vaccine Efforts

Associated Press: Johnson & Johnson Ebola groups get $117M in funding “Johnson & Johnson is working with a slew of organizations to speed up development of an Ebola vaccine, and the company said Friday that a European health organization awarded them $117 million…” (1/16). Financial Times: J&J receives €100m E.U.…

News Summary Read More
The Henry J. Kaiser Family Foundation

7 Key Challenges Face Ebola Vaccine Developers, Stakeholders

The Lancet: Is the world ready for an Ebola vaccine? Bruce Y. Lee of the International Vaccine Access Center at Johns Hopkins Bloomberg School of Public Health and colleagues “…We propose seven key challenges to be considered early in Ebola vaccine development that will help stakeholders prepare and allow developers…

News Summary Read More